Zimmer Biomet Company Top Insiders

ZBH Stock  USD 132.61  4.74  3.71%   
Under 80 percent of all Zimmer Biomet's insiders are aggressively buying. The analysis of insiders' sentiment of trading Zimmer Biomet Holdings stock suggests that a large number of insiders are very bullish at this time. Zimmer Biomet employs about 18 K people. The company is managed by 47 executives with a total tenure of roughly 321 years, averaging almost 6.0 years of service per executive, having 382.98 employees per reported executive.
David Dvorak  CEO
CEO and President and Director
Larry Glasscock  Chairman
Independent Non-Executive Chairman of the Board

Zimmer Biomet's Insider Buying Vs Selling

80

 
Selling
 
Buying

Latest Trades

2024-02-22Chad F PhippsDisposed 26156 @ 128.62View
2023-08-30Sreelakshmi KolliAcquired 1000 @ 120.37View
2023-08-28Robert HagemannAcquired 2000 @ 116.48View
2023-08-25Michael W MichelsonAcquired 1300 @ 115.5View
2023-08-23Arthur J HigginsAcquired 1000 @ 115.61View
Monitoring Zimmer Biomet's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Zimmer Biomet's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Zimmer Biomet's future performance. Based on our forecasts, it is anticipated that Zimmer will maintain a workforce of under 18000 employees by April 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Zimmer Biomet's latest congressional trading

Congressional trading in companies like Zimmer Biomet Holdings, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Zimmer Biomet by those in governmental positions are based on the same information available to the general public.
2022-11-28Representative Van TaylorDisposed $100K to $250KVerify
2022-07-28Representative Lois FrankelDisposed Under $15KVerify
2021-09-30Representative Susie LeeDisposed $15K to $50KVerify
2021-08-06Representative Charles J. "Chuck" FleischmannDisposed Under $15KVerify
2016-12-16Senator Jack ReedAcquired Under $15KVerify

Zimmer Biomet Management Team Effectiveness

The company has Return on Asset of 0.044 % which means that on every $100 spent on assets, it made $0.044 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0836 %, implying that it generated $0.0836 on every 100 dollars invested. Zimmer Biomet's management efficiency ratios could be used to measure how well Zimmer Biomet manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to 0.07. The current Return On Assets is estimated to decrease to 0.05. As of now, Zimmer Biomet's Asset Turnover is decreasing as compared to previous years.
The current Common Stock Shares Outstanding is estimated to decrease to about 164.9 M. The current Net Income Applicable To Common Shares is estimated to decrease to about 252.8 M

Zimmer Biomet Workforce Comparison

Zimmer Biomet Holdings is rated third in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 153,593. Zimmer Biomet retains roughly 18,000 in number of employees claiming about 12% of equities under Health Care industry.

Zimmer Biomet Profit Margins

The company has Net Profit Margin of 0.14 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.24 %, which entails that for every 100 dollars of revenue, it generated $0.24 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.80.6306
Significantly Up
Very volatile
Operating Profit Margin0.220.1876
Fairly Up
Slightly volatile

Zimmer Biomet Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zimmer Biomet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zimmer Biomet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Zimmer Biomet insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
0.75
30
40
 193,004 
 134,290 
2023-12-01
1.0
10
10
 4,346 
 54,956 
2023-09-01
6.6667
20
3
 31,806 
 8,078 
2023-06-01
15.0
30
2
 15,737 
 825.00 
2023-03-01
1.625
26
16
 162,668 
 83,458 
2022-12-01
1.8571
13
7
 17,129 
 26,399 
2022-09-01
2.5
10
4
 6,105 
 8,181 
2022-06-01
15.5
31
2
 22,869 
 698.00 
2022-03-01
9.75
39
4
 467,147 
 64,913 
2021-12-01
0.4839
15
31
 64,115 
 200,119 
2021-09-01
6.0
12
2
 55,755 
 4,767 
2021-06-01
10.0
30
3
 18,583 
 1,677 
2021-03-01
1.5789
30
19
 288,100 
 46,869 
2020-12-01
1.1538
15
13
 44,019 
 79,541 
2020-09-01
3.6667
11
3
 7,069 
 6,288 
2020-06-01
15.5
31
2
 25,622 
 9,717 
2020-03-01
2.3571
33
14
 391,443 
 47,148 
2019-12-01
1.1111
20
18
 32,522 
 48,096 
2019-09-01
1.8571
13
7
 114,086 
 74,745 
2019-06-01
7.5
30
4
 25,796 
 11,639 
2019-03-01
3.5385
46
13
 365,528 
 22,627 
2018-12-01
8.0
16
2
 65,078 
 12,622 
2018-09-01
2.1429
15
7
 61,162 
 71,701 
2018-06-01
3.7143
26
7
 31,431 
 20,582 
2018-03-01
5.8333
35
6
 588,586 
 48,557 
2017-12-01
1.8571
13
7
 339,212 
 25,762 
2017-09-01
1.5556
14
9
 26,361 
 33,282 
2017-06-01
1.7619
37
21
 174,048 
 283,208 
2017-03-01
1.6818
37
22
 523,484 
 270,163 
2016-12-01
5.0
10
2
 6,975 
 10,100 
2016-09-01
0.9167
11
12
 19,968 
 66,618 
2016-06-01
3.0909
34
11
 23,585 
 50,622 
2016-03-01
1.5714
33
21
 574,565 
 40,720,036 
2015-12-01
2.25
9
4
 6,733 
 10,844 
2015-06-01
1.0385
54
52
 798,845 
 209,284 
2015-03-01
1.1429
24
21
 170,302 
 139,375 
2014-12-01
0.875
14
16
 91,430 
 138,016 
2014-09-01
1.6667
10
6
 82,642 
 92,473 

Zimmer Biomet Notable Stakeholders

A Zimmer Biomet stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Zimmer Biomet often face trade-offs trying to please all of them. Zimmer Biomet's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Zimmer Biomet's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David DvorakCEO and President and DirectorProfile
Larry GlasscockIndependent Non-Executive Chairman of the BoardProfile
Bryan HansonChairman of the Board, President, Chief Executive OfficerProfile
Coleman LannumSenior Vice President - Investor RelationsProfile
Matt AbernethyCPA, Vice President Investor RelationsProfile
Ellison HumphreySenior Vice President, Chief Transformation OfficerProfile
Daniel FlorinCFO, Senior Vice PresidentProfile
Robert MarshallVice President - Investor Relations, TreasurerProfile
David NolanGroup President of Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle and Bone HealingProfile
Joseph CucoloPresident AmericasProfile
Derek DavisChief Accounting Officer, Vice President, ControllerProfile
Ivan TornosGroup President - Global Businesses and AmericasProfile
Aure BruneauGroup President Spine, CMF, Thoracic and Surgery Assisting TechnologyProfile
Katarzyna MazurHofsaessPresident Europe, Middle East and AfricaProfile
Suketu UpadhyayChief Financial Officer, Executive Vice PresidentProfile
Sang YiPresident Asia PacificProfile
Adam JohnsonGroup President Spine, Dental, CMF and ThoracicProfile
Daniel WilliamsonGroup President Joint ReconstructionProfile
Chad PhippsSenior Vice President, General Counsel, SecretaryProfile
Tony CollinsChief Accounting Officer, Vice President ControllerProfile
Stuart KleopferPresident AmericasProfile
Robert DelpsPresident AmericasProfile
Arthur HigginsIndependent DirectorProfile
Michael MichelsonIndependent DirectorProfile
Cecil PickettIndependent DirectorProfile
Jeffrey RhodesDirectorProfile
Paul BisaroIndependent DirectorProfile
Christopher BegleyLead Independent DirectorProfile
Betsy BernardIndependent DirectorProfile
Maria HiladoIndependent DirectorProfile
Syed JafryIndependent DirectorProfile
Michael FarrellIndependent DirectorProfile
Zachary CPADirector RelationsProfile
Gail BoudreauxIndependent DirectorProfile
Robert HagemannIndependent DirectorProfile
Angela MainGlobal VPProfile
Sreelakshmi KolliIndependent DirectorProfile
Didier DeltortPresident - Europe, Middle East and AfricaProfile
Carrie NicholChief Accounting Officer, Vice President ControllerProfile
Nitin GoyalChief Science, Technology and Innovation OfficerProfile
Wilfred ZuilenPresident - Europe, Middle East and AfricaProfile
Zeeshan TariqSenior OfficerProfile
Keri MattoxSenior Vice President - Investor Relations, Chief Communications OfficerProfile
Rachel EllingsonSenior Vice President Chief Strategy Officer, Executive OfficerProfile
Nitin MDTechnology ScienceProfile
Paul StellatoController VPProfile
Lori WinklerChief Human Resource Officer, Senior Vice PresidentProfile

About Zimmer Biomet Management Performance

The success or failure of an entity such as Zimmer Biomet Holdings often depends on how effective the management is. Zimmer Biomet management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Zimmer management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Zimmer management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2024
Return On Capital Employed 0.07  0.07 
Return On Assets 0.05  0.05 
Return On Equity 0.08  0.08 
The data published in Zimmer Biomet's official financial statements usually reflect Zimmer Biomet's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Zimmer Biomet Holdings. For example, before you start analyzing numbers published by Zimmer accountants, it's critical to develop an understanding of what Zimmer Biomet's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Zimmer Biomet's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zimmer Biomet's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Zimmer Biomet's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Zimmer Biomet Holdings. Please utilize our Beneish M Score to check the likelihood of Zimmer Biomet's management manipulating its earnings.

Zimmer Biomet Workforce Analysis

Traditionally, organizations such as Zimmer Biomet use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Zimmer Biomet within its industry.

Zimmer Biomet Manpower Efficiency

Return on Zimmer Biomet Manpower

Revenue Per Employee410.8K
Revenue Per Executive157.3M
Net Income Per Employee56.9K
Net Income Per Executive21.8M
Working Capital Per Employee97.3K
Working Capital Per Executive37.3M
When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Zimmer Biomet Holdings information on this page should be used as a complementary analysis to other Zimmer Biomet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Zimmer Stock analysis

When running Zimmer Biomet's price analysis, check to measure Zimmer Biomet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zimmer Biomet is operating at the current time. Most of Zimmer Biomet's value examination focuses on studying past and present price action to predict the probability of Zimmer Biomet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zimmer Biomet's price. Additionally, you may evaluate how the addition of Zimmer Biomet to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Commodity Directory
Find actively traded commodities issued by global exchanges
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Zimmer Biomet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.16)
Dividend Share
0.96
Earnings Share
4.88
Revenue Per Share
35.43
Quarterly Revenue Growth
0.063
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.